Skip to main content

Market Overview

At Long Last, Dynavax Wins FDA Approval For Heplisav

At Long Last, Dynavax Wins FDA Approval For Heplisav

Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine 

The company failed to gain approval for its therapy in February 2013 and in November 2016. But now that the therapy has FDA approval, the company is open to, but not waiting for, a partner to market its new product, CEO Eddie Gray told Reuters.

The Analyst

Cantor Fitzgerald's Elemer Piros, Ph.D.

The Rating

Piros maintains an Overweight rating on Dynavax's stock with a price target boosted from $24 to $25. (See Piros' track record here.) 

The Thesis

Dynavax's FDA approval will be followed up with an anticipated product launch in the first quarter of 2018, Piros said in a Thursday note. The FDA's inclusion of HEPLISAV's positive data in diabetes patients in the package insert is an encouraging factor, the analyst said.

Dynavax is expected to provide further details including pricing closer to the vaccine's launch. 

The company said it has a drug supply of over 250,000 vials of its therapy that will be available prior to the launch, with an additional 750,000 vials worth of raw material on hand, according to Cantor Fitzgerald. The supply is likely sufficient to satisfy two years of demand, giving the drugmaker leeway to produce additional supply over the coming years, Piros said. 

Dynavax is well-capitalized ,with a cash and equivalents balance of $192 million — enough to develop its immuno-oncology pipeline through 2018, the analyst said. 

Price Action

Shares of Dynavax were trading higher by 13 percent early Friday at $22.80.

Related Links:

Dynavax Now Has A De-Risked Asset With Long-Term Potential

Dynavax: Buy On Weakness Ahead Of November's PDUFA Date

Latest Ratings for DVAX

Feb 2021HC Wainwright & Co.MaintainsBuy
Nov 2020HC Wainwright & Co.MaintainsBuy
Aug 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for DVAX
View the Latest Analyst Ratings


Related Articles (DVAX)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald dynavaxAnalyst Color Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

KRYSHC Wainwright & Co.Maintains103.0
OTRKRBC CapitalDowngrades32.0
EVHCanaccord GenuityMaintains24.0
BMRNCanaccord GenuityMaintains91.0
ONTFCanaccord GenuityInitiates Coverage On65.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at